Share This Page
SOYACAL 20% Drug Patent Profile
✉ Email this page to a colleague
When do Soyacal 20% patents expire, and what generic alternatives are available?
Soyacal 20% is a drug marketed by Alpha Thera and is included in one NDA.
The generic ingredient in SOYACAL 20% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SOYACAL 20%?
- What are the global sales for SOYACAL 20%?
- What is Average Wholesale Price for SOYACAL 20%?
Summary for SOYACAL 20%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | SOYACAL 20% at DailyMed |
US Patents and Regulatory Information for SOYACAL 20%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Thera | SOYACAL 20% | soybean oil | INJECTABLE;INJECTION | 018786-001 | Jun 29, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
SOYACAL 20% market dynamics and financial trajectory (20% soap emulsion)
SOYACAL 20% (20% soap emulsion; prescription/OTC status varies by market) is a niche dermatology product with low public financial transparency. Publicly accessible sources do not provide a complete, auditable package of (1) global sales, (2) country-by-country revenue, (3) manufacturing cost of goods, (4) price history, or (5) contribution margins by product strength/formulation. Without that dataset, a complete financial trajectory and market-size model cannot be produced from verifiable facts.
What matters commercially for SOYACAL 20%
- Segment drivers: topical dermatology demand is constrained by indication breadth, channel access (pharmacies vs. institutional procurement), and competitive substitution by other topical keratolytics, antiseborrheics, and emollient/soap-based cleansing products.
- Pricing pressure: topical products face frequent retail repricing and wholesale contract renegotiations, especially where generics and “same active, different brand” substitutes exist.
- Reimbursement and labeling: financial performance typically tracks reimbursement status, formulary inclusion, and whether the product is positioned as a therapeutic (drug) versus a cosmetic/personal-care cleanser.
- Supply continuity: soap-emulsion supply chains are sensitive to surfactant and oil-derivative inputs, packaging, and cold-chain requirements if specified by local labeling.
- Regulatory posture: whether the product is handled as a drug, OTC medicine, or cosmetic/personal care changes the market entry barrier and competitive intensity.
How does SOYACAL 20% perform commercially by region?
Answer: Public sources do not provide a complete, auditable breakdown of SOYACAL 20% sales by geography. A defensible regional trajectory cannot be calculated without verifiable revenue or unit sales by country.
What the market tends to show for similar topical soap-emulsion products
- Higher visibility markets are typically those where topical dermatology products are distributed through mainstream pharmacy networks with stable retail markup rules.
- Lower-visibility markets are those where the product is sold through smaller wholesalers, local tenders, or direct-to-clinic arrangements without public sales reporting.
Channel dynamics to expect
- Pharmacy retail: best predictor of steady demand, but price competition and private-label substitutes can compress margins.
- Institutional procurement: can cause step-changes in volume, with tenders often renegotiated annually or biannually.
- Direct-to-consumer: typically increases volatility because marketing spend and shelf placement dominate short-term outcomes.
What market dynamics affect demand for 20% soap emulsion skin products?
Answer: Demand is most sensitive to (1) therapeutic positioning, (2) formulary/channel access, (3) competitive displacement by alternative topical regimens, and (4) price and promotion cycles.
Therapeutic and use-case dependency
Soap-emulsion topical products generally compete within dermatology cleansing and skin-management niches. Market pull is tied to:
- Indication specificity: whether labeling supports a defined disease state or is broader “skin cleansing” positioning.
- Treatment regimen fit: whether clinicians co-prescribe it with topical keratolytics, antifungals, or anti-inflammatory agents.
- Patient adherence: emulsion texture, irritation profile, and dosing frequency affect repeat purchases.
Competitive substitution vectors
- Alternative cleansing/soap emulsion brands with similar concentration.
- Non-soap emollients and dermocosmetics positioned as “gentler,” which can steal share even when active composition differs.
- Generic topical medicines in overlapping indications if the product is treated as a drug in local regimes.
What is the financial trajectory of SOYACAL 20% over time?
Answer: A complete financial trajectory cannot be produced from verifiable public data. No auditable dataset is available in public channels that ties SOYACAL 20% to historical revenue, units, or margin trends.
What would typically drive trajectory for a topical dermatology product
- Launch and early adoption: initial uptake depends on distribution agreements and physician buy-in.
- Mid-cycle share: stabilizes when the product becomes routine in treatment algorithms.
- Later-cycle pressure: accelerates when new competing actives enter, or when channels shift to private labels or lower-priced equivalents.
Common margin structure risks for topical emulsions
- Ingredient input volatility (surfactants/oils).
- Packaging cost inflation.
- Promotional intensity changes in retail.
- Returns and shelf-life write-offs.
Does SOYACAL 20% face patent or exclusivity constraints that impact sales growth?
Answer: Exclusivity constraints cannot be tied to SOYACAL 20% sales from available public evidence in this context.
Why IP typically matters in topical soap-emulsion markets
Topical cleansing products often have:
- Lower, fragmented patent estates compared with systemically administered drugs.
- Reformulation and process patents that are hard to monetize if multiple generics or “same-category” substitutes exist.
How do regulatory status and market entry barriers affect competition for SOYACAL 20%?
Answer: A full regulatory competitive analysis requires verified jurisdiction-specific classification (drug vs OTC vs cosmetic/personal care) and local approval history, which is not available in this context.
What changes competitive intensity
- If classified as a cosmetic/personal care product, the barrier is usually lower and substitution is faster.
- If classified as a drug/OTC medicine, licensing and labeling scrutiny tend to slow entry and reduce direct competition.
What generic entry risks exist for SOYACAL 20%?
Answer: The generic entry risk cannot be quantified without confirmation of (1) local regulatory classification and (2) the existence of enforceable product-specific IP. No auditable data is available here to map entry pathways to sales exposure.
Entry pathways that typically threaten branded topical products
- Same-strength soap emulsion substitutes with equivalent claims.
- Private-label “derm cleansing” emulsions.
- Reclassified products that compete on labeling and channel position.
How strong is the competitive landscape for 20% soap emulsion products?
Answer: The competitive landscape is inherently fragmented, but a defensible strength-of-competition ranking requires a specific country list of labeled competitors and active-strength match, which is not available here.
Market share dynamics likely to apply
- Brands that secure stable pharmacy placement generally hold higher repeat demand.
- Low-cost substitutes gain traction during retail price rounds.
- Clinician-driven regimens dominate where the product is positioned as part of disease treatment.
What business signals would predict future growth or decline for SOYACAL 20%?
Answer: The following are the most commercially predictive signals for niche topical products, though they are not quantified here due to missing public datasets:
- Distribution expansion (new wholesalers, pharmacy chain adoption).
- Retail pricing stability vs promotional depth (net selling price trend).
- Reimbursement/formulary inclusion if treated as a drug.
- Regulatory or labeling changes that expand or restrict indications.
- Supply chain reliability and any stock-outs.
Key Takeaways
- SOYACAL 20% is a niche dermatology topical product. Public sources do not provide sufficient auditable data to build a complete market-size view, country-level demand map, or revenue/margin time series.
- Market dynamics for similar topical emulsion/cleansing products are dominated by channel access, therapeutic positioning, substitution risk, and pricing cycles rather than large-scale system-wide demand drivers.
- A defensible financial trajectory for SOYACAL 20% cannot be generated from verifiable facts in this context.
FAQs
- Is SOYACAL 20% classified as a drug or cosmetic in major markets?
- What are the most common substitutes for a 20% soap emulsion topical product in pharmacy retail?
- Does SOYACAL 20% compete more on indication claims or on skin-tolerance and cleansing experience?
- What retail pricing and promotional patterns typically compress margins for topical dermatology brands?
- How does channel strategy (pharmacy vs institutional procurement) change SOYACAL 20% demand volatility?
References (APA)
No verifiable, citable sources were provided or identified in this context to support product-specific market sizing, revenue, or financial trajectory for SOYACAL 20%.
More… ↓
